Patents by Inventor Ernesto Guccione

Ernesto Guccione has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS OF TREATING TUMORS AND CANCERS HAVING DYSREGULATED WNT SIGNALING PATHWAYS
    Publication number: 20230404985
    Abstract: The present disclosure relates to methods of treating tumors and cancers having dysregulated Wnt signaling pathways with compounds of Formula (I) having the following structure: (I) or a stereoisomer, pharmaceutically acceptable salt, oxide, or solvate thereof, where X is a halogen and R is a phenyl substituted with a perfluoroalkane. Also disclosed is a method of treating a tumor, which involves contacting a tumor comprising cytoplasmic EZH2 with a kinase inhibitor compound under conditions effective to treat the tumor.
    Type: Application
    Filed: November 2, 2021
    Publication date: December 21, 2023
    Inventors: Ernesto GUCCIONE, Amaia LUJAMBIO, Arvin DAR, Alexander RIALDI, Mary E. DUFFY, Alexander P. SCOPTON, Pedro MOLINA-SANCHEZ, Slim MZOUGHI
  • Method of treating cancer by antisense oligonucleotides targeting PRDM15
    Patent number: 11136579
    Abstract: The present invention relates to antisense oligonucleotides for modulating the activity of PRDM15 and use thereof in the treatment of cancer. In particular, said antisense oligonucleotides are capable of inducing the skipping of an exon of a PRDM15 mRNA. The present invention also relates to a method for determining prognosis in a patient with cancer, or selecting a therapeutic strategy for a patient with cancer, by assessing the level of PRDM15 nucleic acid, protein or activity in a sample.
    Type: Grant
    Filed: September 4, 2017
    Date of Patent: October 5, 2021
    Assignee: AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH
    Inventors: Ernesto Guccione, Keng Boon Dave Wee
  • PROTEIN ARGININE METHYLTRANSFERASE 5 (PRMT5) DEGRADATION / DISRUPTION COMPOUNDS AND METHODS OF USE
    Publication number: 20210261538
    Abstract: Disclosed are protein arginine methyltransferase 5 (PRMT5) degradation/disruption compounds including a PRMT5 ligand, a degradation/disruption tag and a linker, and methods for use of such compounds in the treatment of PRMT5-mediated diseases. The PRMT5 degraders disclosed herein offer a novel mechanism for treating PRMT5-mediated diseases compared to small molecule inhibitors of PRMT5 activity.
    Type: Application
    Filed: February 22, 2019
    Publication date: August 26, 2021
    Inventors: Jian Jin, Jing Liu, Yudao Shen, Ernesto Guccione, Martin Walsh, Almudena Bosch, Megan Schwarz
  • Direct and Selective Inhibition of MDM4 for Treatment of Cancer
    Publication number: 20200392506
    Abstract: The present application relates to the field of cancer, particularly that of cancers with high MDM4 protein levels (such as melanoma, breast, colon or lung cancers, glioblastoma, retinoblastoma, etc.). It is shown herein that direct and selective inhibition of MDM4, e.g., by antisense RNA, leads to growth inhibition of cancer cells and sensitization to chemo or targeted therapies. Also provided are simple ways of determining which patients are most amenable for such treatment by comparing specific transcript levels.
    Type: Application
    Filed: August 21, 2020
    Publication date: December 17, 2020
    Inventors: Jean-Christophe Marine, Ernesto Guccione, Marco Bezzi
  • Direct and selective inhibition of MDM4 for treatment of cancer
    Patent number: 10767182
    Abstract: The present application relates to the field of cancer, particularly that of cancers with high MDM4 protein levels (such as melanoma, breast, colon or lung cancers, glioblastoma, retinoblastoma, etc.). It is shown herein that direct and selective inhibition of MDM4, e.g., by antisense RNA, leads to growth inhibition of cancer cells and sensitization to chemo or targeted therapies. Also provided are simple ways of determining which patients are most amenable for such treatment by comparing specific transcript levels.
    Type: Grant
    Filed: November 16, 2015
    Date of Patent: September 8, 2020
    Assignees: VIB VZW, Katholieke Universiteit Leuven, K.U.Leuven R&D, Agency for Science, Technology and Research
    Inventors: Jean-Christophe Marine, Ernesto Guccione, Marco Bezzi
  • METHOD OF TREATING CANCER BY ANTISENSE OLIGONUCLEOTIDES TARGETING PRDM15
    Publication number: 20200181612
    Abstract: The present invention relates to antisense oligonucleotides for modulating the activity of PRDM15 and use thereof in the treatment of cancer. In particular, said antisense oligonucleotides are capable of inducing the skipping of an exon of a PRDM15 mRNA. The present invention also relates to a method for determining prognosis in a patient with cancer, or selecting a therapeutic strategy for a patient with cancer, by assessing the level of PRDM15 nucleic acid, protein or activity in a sample.
    Type: Application
    Filed: September 4, 2017
    Publication date: June 11, 2020
    Applicant: AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH
    Inventors: Ernesto GUCCIONE, Keng Boon Dave WEE
  • DIRECT AND SELECTIVE INHIBITION OF MDM4 FOR TREATMENT OF CANCER
    Publication number: 20170314024
    Abstract: The present application relates to the field of cancer, particularly that of cancers with high MDM4 protein levels (such as melanoma, breast, colon or lung cancers, glioblastoma, retinoblastoma, etc.). It is shown herein that direct and selective inhibition of MDM4, e.g., by antisense RNA, leads to growth inhibition of cancer cells and sensitization to chemo or targeted therapies. Also provided are simple ways of determining which patients are most amenable for such treatment by comparing specific transcript levels.
    Type: Application
    Filed: November 16, 2015
    Publication date: November 2, 2017
    Inventors: Jean-Christophe Marine, Ernesto Guccione, Marco Bezzi